Go Pro
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel Free CANF Stock Alerts

Can-Fite BioPharma (CANF) Competitors

Can-Fite BioPharma logo
$2.24 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.24 +0.00 (+0.04%)
As of 09/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CANF vs. PCSA, PULM, ADXN, INM, and SBFM

Should you buy Can-Fite BioPharma stock or one of its competitors? Can-Fite BioPharma's main competitors and comparable companies include Heatwurx (PCSA), Pulmatrix (PULM), Addex Therapeutics (ADXN), InMed Pharmaceuticals (INM), and Sunshine Biopharma (SBFM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Can-Fite BioPharma compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Heatwurx has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Can-Fite BioPharma's return on equity of 0.00% beat Heatwurx's return on equity.

Company Net Margins Return on Equity Return on Assets
HeatwurxN/A -394.25% -244.46%
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has higher revenue and earnings than Heatwurx. Heatwurx is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeatwurxN/AN/A-$13.56M-$4.23N/A
Can-Fite BioPharma$405K3.62-$7.63M-$22.80N/A

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Heatwurx. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
Heatwurx Neutral
Can-Fite BioPharma Neutral

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,864.29%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Heatwurx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heatwurx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Can-Fite BioPharma beats Heatwurx on 9 of the 13 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Pulmatrix has higher revenue and earnings than Can-Fite BioPharma. Pulmatrix is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmatrix$7.81M0.67-$5.16M-$1.10N/A
Can-Fite BioPharma$405K3.62-$7.63M-$22.80N/A

Pulmatrix has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Can-Fite BioPharma's return on equity of 0.00% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
PulmatrixN/A -125.65% -95.19%
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 1,864.29%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Pulmatrix. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
Pulmatrix Neutral
Can-Fite BioPharma Neutral

Summary

Can-Fite BioPharma beats Pulmatrix on 10 of the 14 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
Addex Therapeutics Neutral
Can-Fite BioPharma Neutral

Addex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Can-Fite BioPharma has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K19.91-$8.12M-$5.94N/A
Can-Fite BioPharma$405K3.62-$7.63M-$22.80N/A

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Can-Fite BioPharma has a consensus target price of $44.00, indicating a potential upside of 1,864.29%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Can-Fite BioPharma's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -134.76% -106.00%
Can-Fite BioPharma N/A N/A N/A

Summary

Can-Fite BioPharma beats Addex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Can-Fite BioPharma compare to InMed Pharmaceuticals?

Can-Fite BioPharma (NYSE:CANF) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Can-Fite BioPharma's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
InMed Pharmaceuticals N/A -156.08%-123.90%

In the previous week, InMed Pharmaceuticals had 5 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 6 mentions for InMed Pharmaceuticals and 1 mentions for Can-Fite BioPharma. InMed Pharmaceuticals' average media sentiment score of 0.39 beat Can-Fite BioPharma's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Can-Fite BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
InMed Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Can-Fite BioPharma has higher earnings, but lower revenue than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K3.62-$7.63M-$22.80N/A
InMed Pharmaceuticals$4.94M0.91-$12.56M-$1.64N/A

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 1,864.29%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than InMed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
InMed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Can-Fite BioPharma beats InMed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Sunshine Biopharma?

Can-Fite BioPharma (NYSE:CANF) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Can-Fite BioPharma currently has a consensus price target of $44.00, suggesting a potential upside of 1,864.29%. Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 7,679.51%. Given Sunshine Biopharma's higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Can-Fite BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Sunshine Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Can-Fite BioPharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K3.62-$7.63M-$22.80N/A
Sunshine Biopharma$36.31M0.10-$5.97M-$10.15N/A

Can-Fite BioPharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Can-Fite BioPharma's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Sunshine Biopharma -17.94%-26.36%-20.60%

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Sunshine Biopharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Sunshine Biopharma Neutral

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Can-Fite BioPharma beats Sunshine Biopharma on 8 of the 15 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CANF vs. The Competition

Export
MetricCan-Fite BioPharmaPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$1.47M$12.47B$7.24B$23.10B
Dividend YieldN/A2.64%2.57%3.62%
P/E Ratio-1.25797.25275.4928.21
Price / Sales3.62753.62646.0120.34
Price / CashN/A86.3676.2536.36
Price / Book1.2710.5310.464.67
Net Income-$7.63M$2.82B$3.49B$1.07B
7 Day Performance-3.86%1.69%0.59%-1.64%
1 Month Performance-33.13%0.24%-1.74%-3.60%
1 Year Performance-82.80%3.95%18.13%8.41%

Can-Fite BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CANF
Can-Fite BioPharma
1.6861 of 5 stars		$2.24
flat		$44.00
+1,864.3%		-82.8%$1.47M$405KN/A5
PCSA
Heatwurx
1.553 of 5 stars		$2.08
-3.7%		N/A-59.5%$5.76MN/AN/A20
PULM
Pulmatrix
0.2281 of 5 stars		$1.54
+10.4%		N/A-71.1%$5.62M$7.81MN/A20
ADXN
Addex Therapeutics
0.8145 of 5 stars		$3.65
-1.4%		N/A-62.1%$4.50M$29.97KN/A30
INM
InMed Pharmaceuticals
1.4549 of 5 stars		$1.34
+0.8%		N/A-40.6%$4.44M$4.94MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:CANF) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel